Filtered By:
Condition: Thrombosis
Infectious Disease: COVID-19

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 1369 results found since Jan 2013.

Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic
CONCLUSION: Rates of some clinical outcomes during the pandemic changed and should not be used as historical background rates in vaccine safety studies. Inclusion of telehealth visits should be considered for vaccine studies involving Bell's palsy, ITP, and narcolepsy/cataplexy.PMID:35465977 | DOI:10.1016/j.vaccine.2022.04.037
Source: Vaccine - April 25, 2022 Category: Allergy & Immunology Authors: Stanley Xu Vennis Hong Lina S Sy Sungching C Glenn Denison S Ryan Kerresa L Morrissette Jennifer C Nelson Simon J Hambidge Bradley Crane Ousseny Zerbo Malini B DeSilva Jason M Glanz James G Donahue Elizabeth Liles Jonathan Duffy Lei Qian Source Type: research

Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): An interrupted time series analysis (January 2019 - February 2021)
Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.PMID:35582854 | DOI:10.1080/03007995.2022.2078100
Source: Current Medical Research and Opinion - May 18, 2022 Category: Research Authors: Sajidah Alkhameys Ravina Barrett Source Type: research

Venovenous extracorporeal membrane oxygenation for coronavirus disease 2019 patients: A systematic review and meta-analysis
CONCLUSION: Although COVID-19 patients may have a higher risk of bleeding, hemorrhagic stroke, and acute kidney injury during ECMO therapy, the survival rate was more than half of the cases. Our data may support the application of VV-ECMO in COVID-19 patients.PMID:35608047 | DOI:10.1177/02676591221104302
Source: Perfusion - May 24, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Kerong Zhai Xu Xu Pengbin Zhang Shilin Wei Jian Li Xiangyang Wu Bingren Gao Yanhua Zhang Yongnan Li Source Type: research

Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study
CONCLUSION: This study shows acceptable safety profiles of COVID-19 vaccines among recipients of BNT162b2, CoronaVac, and ChAdOx1 vaccines. This information can be used together with effectiveness data for risk-benefit analysis of the vaccination program. Further surveillance with more data is required to assess AESIs following COVID-19 vaccination in short- and long-term.PMID:35667917 | DOI:10.1016/j.vaccine.2022.05.075
Source: Vaccine - June 6, 2022 Category: Allergy & Immunology Authors: Norazida Ab Rahman Ming Tsuey Lim Fei Yee Lee Sing Chet Lee Azuana Ramli Siti Nurhafizah Saharudin Teck Long King Emelyne Bani Anak Jam Nor Aliya Ayub Raj Kumar Sevalingam Rashidah Bahari Nor Nadziroh Ibrahim Fatihah Mahmud Sheamini Sivasampu Kalaiarasu M Source Type: research

Carotid free-floating thrombus during COVID-19 vaccine era: causality or not?
AbstractCarotid free-floating thrombus (FFT) is very rarely diagnosed in patients with acute ischemic stroke. It is a real clinical emergency due to the significant risk of death associated with thromboembolic complications. Herein, we present three patients with ischemic stroke caused by carotid FFT after less than 20  days from administration of mRNA vaccine BNT162b1 (Pfizer/BioNTech) for Severe Acute Respiratory Syndrome—CoronaVirus 2 (SARS-CoV-2). To our knowledge, these are the first cases reporting carotid FTT following SARS-CoV-2 vaccination.
Source: Neurological Sciences - August 3, 2022 Category: Neurology Source Type: research

Cerebral venous thrombosis after COVID-19 vaccination: the role for endovascular treatment
Cerebral venous thrombosis (CVT) is a unique cause of stroke. Population-based studies demonstrate an incidence of clinically significant CVT of 1.3–1.5 per 100 000 per year.1 2 This may be an underestimated incidence, as these studies were not based on review of imaging and the often benign nature of this entity may lead to underdiagnoses. In the JNIS paper published by Cleaver et al,3 the authors describe their experience with endovascular treatment (EVT) in patients with cerebral venous sinus thrombosis in patients following COVID-19 vaccination. CVT-related stroke primarily affects young adult and middle-aged pat...
Source: Journal of NeuroInterventional Surgery - August 12, 2022 Category: Neurosurgery Authors: Mahajan, A., Hirsch, J. A. Tags: COVID-19 Commentary Source Type: research

200 Covid-19 and acute ischaemic strokes in CADASIL: a systematic review of the literature
Conclusions This systematic review describes the pattern of COVID-19 associated AIS in CADASIL. Such multiple infarcts, primarily affecting the internal borderzones, have been described in patients with Covid-19 without CADASIL. We discuss possible pathophysiological mechanisms, which may be extrapolated to patients with cerebral small vessel disease, including endothelial injury causing microvascular thrombosis and hypoperfusion due to cerebral blood flow dysautoregulation.
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 12, 2022 Category: Neurosurgery Authors: Noui, Y., Williams, O., Chan, N., Chandra, J., Sztriha, L. Tags: Poster presentations Source Type: research

A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS).
Conclusion: The GARDEN study was set up to tackle a global Public Health emergency. Glenzocimab was safe in doses three times higher than used in stroke. Albeit efficacy was not shown, overall, GARDEN provides insights into Cov-ARDS.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Pottecher, J., Sato, V. A. H., Pletan, Y., Comenducci, A., Desort-Henin, V., Jandrot-Perrus, M., Binay, S., Meilhoc, A., Avenard, G. Tags: 02.01 - Acute critical care Source Type: research

Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank
Conclusions Individuals hospitalised with COVID-19 have increased risk of incident cardiovascular events across a range of disease and mortality outcomes. The risk of most events is highest in the early postinfection period. Individuals not requiring hospitalisation have increased risk of VTE, but not of other cardiovascular-specific outcomes.
Source: Heart - December 22, 2022 Category: Cardiology Authors: Raisi-Estabragh, Z., Cooper, J., Salih, A., Raman, B., Lee, A. M., Neubauer, S., Harvey, N. C., Petersen, S. E. Tags: Open access, Editor's choice, Press releases, COVID-19 Cardiac risk factors and prevention Source Type: research

Risk factors for post-discharge major thromboembolism and mortality in hospitalized patients with COVID-19 with cardiovascular comorbidities
Conclusions COVID-19 inpatients with cardiovascular disease experience high rates of ATE, VTE, or ACM through 90 days post-discharge. Age > 75 years, PAD, CAS, CHF, previous VTE, and ICU admission are independent risk factors.PMID:37146648 | DOI:10.1055/a-2087-3003
Source: Thrombosis and Haemostasis - May 5, 2023 Category: Hematology Authors: Dimitrios Giannis Mark Goldin Husneara Rahman Cristina P Sison Martin Lesser Sam Ngu James Tsang Michael Qiu Shreya Sanghani Jackson Yeh Miltiadis Matsagkas Eleni Arnaoutoglou Alex C Spyropoulos Source Type: research